90%Confidence
0Views
FDASource
2026-04-10Date
Summary
Teva's third Octreotide Acetate recall (30 mg) confirms widespread sterility issues at Pharmathen International, severely impacting Teva's product line and indicating possible FDA enforcement actions. This may necessitate costly remediation efforts and shift market demand to competitors' somatostatin analogs.
Actionable: Avoid Teva's Octreotide Acetate products and explore competitor offerings like Novartis' Sandostatin for patient needs.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now